Laminar Pharma

Laminar Pharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines that act through the innovative therapeutic strategy known as Membrane-Lipid Therapy (MLT). Laminar Pharma arose in 2006 as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba. Laminar Pharma aims to develop next-generation medicines, nutraceutical and cosmetic products based on the novel Membrane-Lipid Therapy (MLT) strategy, which targets membrane lipids and/or the structures they form,...

Design,research and development of innovative molecules based on the novel therapeutic approach,the membrane lipid therapy (mlt)

Laminar pharma operates in the Biotechnology research industry.

Laminar pharma's revenue is 11m - 100m

Laminar pharma has 11 - 50 employees.